Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Dec 12, 2024 10:15am EST

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Dec 09, 2024 12:00pm EST

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Dec 03, 2024 7:30am EST

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Nov 25, 2024 4:15pm EST

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Nov 22, 2024 8:00am EST

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Nov 20, 2024 7:30am EST

Aptose Reports Results for the Third Quarter 2024

Nov 08, 2024 4:01pm EST

Aptose Announces Results from Special Meeting of Shareholders

Sep 05, 2024 4:15pm EDT

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aug 30, 2024 4:30pm EDT

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aug 15, 2024 4:30pm EDT